

# Amit Maity

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1029632/publications.pdf>

Version: 2024-02-01

117  
papers

10,493  
citations

61687

45  
h-index

37326

100  
g-index

117  
all docs

117  
docs citations

117  
times ranked

18909  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transient expansion and myofibroblast conversion of adipogenic lineage precursors mediate bone marrow repair after radiation. JCI Insight, 2022, 7, .	2.3	7
2	Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. Oncologist, 2022, 27, 799-808.	1.9	3
3	Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. Journal of the National Cancer Institute, 2021, 113, 162-170.	3.0	81
4	Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica, 2021, 106, 1705-1713.	1.7	34
5	Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of SÅ©zary Syndrome. JAMA Dermatology, 2021, 157, 90.	2.0	9
6	Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration. International Journal of Radiation Oncology Biology Physics, 2021, 109, 220-230.	0.4	7
7	Early Changes in Physical Activity and Quality of Life With Thoracic Radiation Therapy in Breast Cancer, Lung Cancer, and Lymphoma. International Journal of Radiation Oncology Biology Physics, 2021, 109, 946-952.	0.4	7
8	Cherenkov imaging for total skin electron therapy: an evaluation of dose uniformity. , 2021, 11628, .		2
9	Abstract IA-019: Preclinical studies with proton FLASH radiotherapy in mice and canines: Biological effects, biophysical considerations and potential mechanisms. , 2021, , .		0
10	Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. Cancer, 2021, 127, 2279-2293.	2.0	9
11	Palliative Radiotherapy for Diffuse Large B-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 650-658.	0.2	6
12	Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas. Frontiers in Oncology, 2021, 11, 716002.	1.3	5
13	FLASH Proton Radiotherapy Spares Normal Epithelial and Mesenchymal Tissues While Preserving Sarcoma Response. Cancer Research, 2021, 81, 4808-4821.	0.4	77
14	Comparison of FLASH Proton Entrance and the Spread-Out Bragg Peak Dose Regions in the Sparing of Mouse Intestinal Crypts and in a Pancreatic Tumor Model. Cancers, 2021, 13, 4244.	1.7	48
15	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6580-6590.	3.2	15
16	Estrogen Receptor Î²-Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer. Cancer Research, 2021, 81, 2399-2414.	0.4	7
17	A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. Oncoimmunology, 2021, 10, 1863631.	2.1	16
18	Cherenkov imaging for total skin electron therapy (TSET). Medical Physics, 2020, 47, 201-212.	1.6	22

#	ARTICLE	IF	CITATIONS
19	Management and outcomes of sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman) Tj ETQq1 1 0.784314 rgBT /Overlook	0.6	14
20	Impact of Radiotherapy on Hospitalization Burden Surrounding Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, E51-E52.	0.4	1
21	Combining Radiation with Immunotherapy: The University of Pennsylvania Experience. Seminars in Radiation Oncology, 2020, 30, 173-180.	1.0	6
22	Design, Implementation, and in Vivo Validation of a Novel Proton FLASH Radiation Therapy System. International Journal of Radiation Oncology Biology Physics, 2020, 106, 440-448.	0.4	274
23	Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation. Oncogene, 2020, 39, 4344-4357.	2.6	22
24	Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, 178-188.	0.4	60
25	Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 1464.	3.4	28
26	Acute neurologic toxicity of palliative radiotherapy for brain metastases in patients receiving immune checkpoint blockade. Neuro-Oncology Practice, 2019, 6, 297-304.	1.0	12
27	Early Changes in Cardiovascular Biomarkers with Contemporary Thoracic Radiation Therapy for Breast Cancer, Lung Cancer, and Lymphoma. International Journal of Radiation Oncology Biology Physics, 2019, 103, 851-860.	0.4	53
28	A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy. Blood, 2019, 134, 4108-4108.	0.6	14
29	Plasma D-Dimer Levels are Elevated in Radiation Oncology Patients. Radiation Research, 2019, 193, 46.	0.7	5
30	Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients. Blood, 2019, 134, 2905-2905.	0.6	2
31	The Future of Radiobiology. Journal of the National Cancer Institute, 2018, 110, 329-340.	3.0	76
32	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. British Journal of Cancer, 2018, 119, 1200-1207.	2.9	83
33	Tolerability of sequential immune therapy and palliative radiotherapy to the cervical and thoracic spine. Journal of Radiation Oncology, 2018, 7, 233-239.	0.7	2
34	Cherenkov imaging for Total Skin Electron Therapy (TSET)., 2018, , .		5
35	A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Cancer, 2017, 123, 1363-1371.	2.0	18
36	Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. Annals of Oncology, 2017, 28, 2179-2184.	0.6	44

#	ARTICLE	IF	CITATIONS
37	Transcriptome analysis of hypoxic cancer cells uncovers intron retention in EIF2B5 as a mechanism to inhibit translation. <i>PLoS Biology</i> , 2017, 15, e2002623.	2.6	41
38	Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. <i>Cell</i> , 2016, 167, 1540-1554.e12.	13.5	830
39	Journey Toward High Reliability: A Comprehensive Safety Program to Improve Quality of Care and Safety Culture in a Large, Multisite Radiation Oncology Department. <i>Journal of Oncology Practice</i> , 2016, 12, e603-e612.	2.5	14
40	An automated electronic system for managing radiation treatment plan peer review reduces missed reviews at a large, high-volume academic center. <i>Practical Radiation Oncology</i> , 2016, 6, e307-e314.	1.1	6
41	A Review of Radiation-Induced Coagulopathy and New Findings to Support Potential Prevention Strategies and Treatments. <i>Radiation Research</i> , 2016, 186, 121-140.	0.7	37
42	The implementation and assessment of a quality and safety culture education program in a large radiation oncology department. <i>Practical Radiation Oncology</i> , 2016, 6, e127-e134.	1.1	14
43	A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT). <i>Blood</i> , 2016, 128, 4165-4165.	0.6	5
44	Modeling Long-Term Survival in Chemotherapy-Only Versus Combined Modality Therapy in Patients with Early Stage Unfavorable Hodgkin Lymphoma Involving the Mediastinum. <i>Blood</i> , 2016, 128, 2356-2356.	0.6	0
45	Incident Learning in Pursuit of High Reliability: Implementing a Comprehensive, Low-Threshold Reporting Program in a Large, Multisite Radiation Oncology Department. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2015, 41, 160-AP1.	0.4	14
46	The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1 $\alpha$ Phosphorylation. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1928-1938.	1.9	54
47	Factors associated with event reporting in the pediatric radiation oncology population using an electronic incident reporting system. <i>Practical Radiation Oncology</i> , 2015, 5, e417-e422.	1.1	4
48	Awakening the immune system with radiation: Optimal dose and fractionation. <i>Cancer Letters</i> , 2015, 368, 185-190.	3.2	91
49	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. <i>Nature</i> , 2015, 520, 373-377.	13.7	1,955
50	Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy Efficacy via Reduction in Oxygen Demand. <i>Clinical Cancer Research</i> , 2015, 21, 1995-2000.	3.2	43
51	Consolidative Radiation Therapy Following Autologous Transplantation in Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 3195-3195.	0.6	2
52	Galectin-1 and Immune Suppression during Radiotherapy. <i>Clinical Cancer Research</i> , 2014, 20, 6230-6232.	3.2	8
53	A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2014, 116, 365-372.	1.4	29
54	Radiotherapy and the Tumor Microenvironment: Mutual Influence and Clinical Implications. <i>Advances in Experimental Medicine and Biology</i> , 2014, 772, 147-165.	0.8	38

#	ARTICLE	IF	CITATIONS
55	Cancer of the Central Nervous System. , 2014, , 938-1001.e16.		1
56	Onset of mandible and tibia osteoradionecrosis: a comparative pilot study in the rat. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 115, 201-211.	0.2	22
57	Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235. Molecular Pharmacology, 2012, 82, 1230-1240.	1.0	78
58	Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1 $\alpha$ expression by blocking protein translation and increases cell death under hypoxia. Cancer Biology and Therapy, 2012, 13, 1102-1111.	1.5	33
59	A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response. Journal of Thoracic Oncology, 2012, 7, 709-715.	0.5	68
60	ER stress $\alpha$ -mediated autophagy promotes Myc-dependent transformation and tumor growth. Journal of Clinical Investigation, 2012, 122, 4621-4634.	3.9	336
61	PI3K/AKT/mTOR Pathway in Angiogenesis. Frontiers in Molecular Neuroscience, 2011, 4, 51.	1.4	1,002
62	New Strategies in Non $\alpha$ -Small Cell Lung Cancer: Improving Outcomes in Chemoradiotherapy for Locally Advanced Disease. Clinical Cancer Research, 2011, 17, 4192-4199.	3.2	17
63	<i>In Vivo</i> Profiling of Hypoxic Gene Expression in Gliomas Using the Hypoxia Marker EF5 and Laser-capture Microdissection. Cancer Research, 2011, 71, 779-789.	0.4	47
64	The Tumor Microenvironment in Non $\alpha$ -Small-Cell Lung Cancer. Seminars in Radiation Oncology, 2010, 20, 156-163.	1.0	108
65	Location, Location, Location-Makes All the Difference for Hypoxia in Lung Tumors. Clinical Cancer Research, 2010, 16, 4685-4687.	3.2	11
66	Modulating Tumor Vasculature through Signaling Inhibition to Improve Cytotoxic Therapy: Figure 1.. Cancer Research, 2010, 70, 2141-2145.	0.4	29
67	Epidermal Growth Factor Receptor Inhibition Modulates the Microenvironment by Vascular Normalization to Improve Chemotherapy and Radiotherapy Efficacy. PLoS ONE, 2009, 4, e6539.	1.1	110
68	Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biology and Therapy, 2009, 8, 1994-2001.	1.5	88
69	Increasing Sensitivity to Radiotherapy and Chemotherapy by Using Novel Biological Agents that Alter the Tumor Microenvironment. Current Molecular Medicine, 2009, 9, 1034-1045.	0.6	56
70	Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck. Head and Neck, 2009, 31, 406-411.	0.9	21
71	Radiation Response in Two HPV-Infected Head-and-Neck Cancer Cell Lines in Comparison to a Non $\alpha$ -HPV-Infected Cell Line and Relationship to Signaling Through AKT. International Journal of Radiation Oncology Biology Physics, 2009, 74, 928-933.	0.4	93
72	GENERAL PRINCIPLES OF RADIATION AND CHEMORADIATION. Retina, 2009, 29, S30-S31.	1.0	2

#	ARTICLE	IF	CITATIONS
73	MODULATING THE TUMOR MICROENVIRONMENT TO IMPROVE RADIOTHERAPY. <i>Retina</i> , 2009, 29, S32-S33.	1.0	0
74	Radiation Therapy for Sarcomas. , 2009, , 277-284.		0
75	M-CSF Signals through the MAPK/ERK Pathway via Sp1 to Induce VEGF Production and Induces Angiogenesis In Vivo. <i>PLoS ONE</i> , 2008, 3, e3405.	1.1	87
76	Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation. <i>Journal of Biological Chemistry</i> , 2007, 282, 21206-21212.	1.6	199
77	Detection of Reactive Oxygen Species via Endogenous Oxidative Pentose Phosphate Cycle Activity in Response to Oxygen Concentration. <i>Journal of Biological Chemistry</i> , 2007, 282, 36790-36796.	1.6	67
78	Aiding and ABTâ€™™ing treatment for glioblastoma. <i>Cancer Biology and Therapy</i> , 2007, 6, 802-804.	1.5	1
79	Phosphatase and Tensin Homologue Deficiency in Glioblastoma Confers Resistance to Radiation and Temozolomide that Is Reversed by the Protease Inhibitor Nelfinavir. <i>Cancer Research</i> , 2007, 67, 4467-4473.	0.4	118
80	Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation. <i>Cancer Biology and Therapy</i> , 2007, 6, 156-159.	1.5	18
81	Cellular responses to EGFR inhibitors and their relevance to cancer therapy. <i>Cancer Letters</i> , 2007, 254, 165-177.	3.2	143
82	The HIV Protease Inhibitor Nelfinavir Downregulates Akt Phosphorylation by Inhibiting Proteasomal Activity and Inducing the Unfolded Protein Response. <i>Neoplasia</i> , 2007, 9, 271-278.	2.3	110
83	Childhood intracranial ependymoma. <i>Cancer</i> , 2007, 110, 432-441.	2.0	71
84	HIV Protease Inhibitors Decrease VEGF/HIF-1â€™± Expression and Angiogenesis in Glioblastoma Cells. <i>Neoplasia</i> , 2006, 8, 889-895.	2.3	78
85	2-deoxy-glucose and radiation: Teaching an old DOG new tricks?. <i>Cancer Biology and Therapy</i> , 2006, 5, 824-826.	1.5	13
86	Pulmonary function abnormalities in children treated with whole lung irradiation. <i>Pediatric Blood and Cancer</i> , 2006, 46, 222-227.	0.8	54
87	The chemokine receptor CXCR4: A homing device for hypoxic cancer cells?. <i>Cancer Biology and Therapy</i> , 2006, 5, 1563-1565.	1.5	6
88	EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1â€™± Independent and HIF-1â€™± Dependent Mechanisms. <i>Cancer Research</i> , 2006, 66, 3197-3204.	0.4	256
89	Akt1 Activation Can Augment Hypoxia-Inducible Factor-1â€™± Expression by Increasing Protein Translation through a Mammalian Target of Rapamycinâ€™± Independent Pathway. <i>Molecular Cancer Research</i> , 2006, 4, 471-479.	1.5	167
90	Regulation of Histone Deacetylase 4 Expression by the SP Family of Transcription Factors. <i>Molecular Biology of the Cell</i> , 2006, 17, 585-597.	0.9	41

#	ARTICLE	IF	CITATIONS
91	Nelfinavir Down-regulates Hypoxia-Inducible Factor 1 $\alpha$ and VEGF Expression and Increases Tumor Oxygenation: Implications for Radiotherapy. <i>Cancer Research</i> , 2006, 66, 9252-9259.	0.4	147
92	HIF and MIF--a nifty way to delay senescence?. <i>Genes and Development</i> , 2006, 20, 3337-3341.	2.7	17
93	Effects of hyperbaric oxygen exposure on experimental head and neck tumor growth, oxygenation, and vasculature. <i>Head and Neck</i> , 2005, 27, 362-369.	0.9	23
94	Ionizing radiation inhibits tumor neovascularization by inducing ineffective angiogenesis. <i>Cancer Biology and Therapy</i> , 2005, 4, 1395-1400.	1.5	53
95	Sp1 Is Involved in Akt-mediated Induction of VEGF Expression through an HIF-1 $\alpha$ -independent Mechanism. <i>Molecular Biology of the Cell</i> , 2004, 15, 4841-4853.	0.9	206
96	Treatment of Pediatric Intracranial Arteriovenous Malformations with Linear-Accelerator-Based Stereotactic Radiosurgery: The University of Pennsylvania Experience. <i>Pediatric Neurosurgery</i> , 2004, 40, 207-214.	0.4	43
97	Testicular Seminoma 16 Years After Treatment for CNS Germinoma. <i>Journal of Neuro-Oncology</i> , 2004, 70, 83-85.	1.4	11
98	Craniospinal radiation in the treatment of biopsy-proven intracranial germinomas: twenty-five years' experience in a single center. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1165-1170.	0.4	108
99	Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 714-720.	0.4	275
100	Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas. <i>Cancer</i> , 2004, 101, 817-824.	2.0	91
101	Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 1294-1299.	0.4	22
102	PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. <i>Cancer Research</i> , 2003, 63, 236-41.	0.4	120
103	Hypoxia and VEGF mRNA Expression in Human Tumors. <i>Neoplasia</i> , 2001, 3, 500-508.	2.3	50
104	Low pO <sub>2</sub> and 1 $\beta$ -Estradiol Induce VEGF in MCF-7 and MCF-7-5C Cells: Relationship to in vivo Hypoxia. <i>Breast Cancer Research and Treatment</i> , 2001, 67, 51-60.	1.1	23
105	Regulation of glut1 mRNA by Hypoxia-inducible Factor-1. <i>Journal of Biological Chemistry</i> , 2001, 276, 9519-9525.	1.6	633
106	Decreased cyclin B1 expression contributes to G <sub>2</sub> delay in human brain tumor cells after treatment with camptothecin. <i>Neuro-Oncology</i> , 2001, 3, 11-21.	0.6	3
107	Both Increased Stability and Transcription Contribute to the Induction of the Urokinase Plasminogen Activator Receptor (uPAR) Message by Hypoxia. <i>Experimental Cell Research</i> , 2000, 255, 250-257.	1.2	35
108	Identification of Putative c-Myc-Responsive Genes: Characterization of <i>hMyc1</i> , a Novel Growth-Related Gene. <i>Molecular and Cellular Biology</i> , 1997, 17, 4967-4978.	1.1	131

#	ARTICLE	IF	CITATIONS
109	Potential molecular targets for manipulating the radiation response. International Journal of Radiation Oncology Biology Physics, 1997, 37, 639-653.	0.4	110
110	Effects of ionizing radiation on cell cycle progression. Radiation and Environmental Biophysics, 1995, 34, 79-83.	0.6	133
111	Cell Cycle-dependent Regulation of the Cyclin B1 Promoter. Journal of Biological Chemistry, 1995, 270, 28419-28424.	1.6	100
112	The effects of radiation on the expression of a newly cloned and characterized rat cyclin B mRNA. International Journal of Radiation Oncology Biology Physics, 1994, 28, 135-144.	0.4	25
113	Alternate Polyadenylation in Rodent Cells Results in Two Differentially Expressed Cyclin B1 mRNAs. Biochemical and Biophysical Research Communications, 1994, 202, 908-914.	1.0	6
114	The molecular basis for cell cycle delays following ionizing radiation: a review. Radiotherapy and Oncology, 1994, 31, 1-13.	0.3	275
115	Increased Expression of Cyclin B1 mRNA Coincides with Diminished G <sub>2</sub> -Phase Arrest in Irradiated HeLa Cells Treated with Staurosporine or Caffeine. Radiation Research, 1994, 140, 393.	0.7	30
116	Mediastinal masses in children with Hodgkin's disease. An analysis of the Children's hospital of philadelphia and the hospital of the university of pennsylvania experience. Cancer, 1992, 69, 2755-2760.	2.0	15
117	Shining a FLASHlight on Ultrahigh Dose-Rate Radiation and Possible Late Toxicity. Clinical Cancer Research, 0, , OF1-OF3.	3.2	4